Literature DB >> 24370966

Should African Americans with hypertension be treated differently than non-African Americans?

John M Flack1, Brian A Ference, Phillip Levy.   

Abstract

African Americans have a higher burden of hypertension, more severe blood pressure (BP) elevations, more concurrent risk-enhancing co-morbidities (e.g., diabetes), sub-clinical vascular injury at lower non-hypertensive BP levels, lower BP control rates, and significantly greater risk for adverse pressure-related clinical complications (e.g., stroke, heart failure) than whites. Randomized prospective data from hypertension endpoint trials show a virtually identical percentage reduction in CVD risk for a given magnitude of BP lowering, irrespective of the presence or absence of pre-treatment CVD across a broad range of BP down to pre-treatment BP levels of 110/70 mm Hg. These data, mostly emanating from white populations, do not necessarily inform practitioners as to the level below which BP should be lowered in those with established, long-standing hypertension; however, these data do provide support for initiating hypertension treatment at lower than conventional BP thresholds. A Mendelian randomized study examining the impact of life-long lower SBP levels showed that lifelong exposure to 10 mm Hg lower SBP was associated with an 82 % lesser rate of SBP rise per decade and a 58 % lower CHD risk that was much greater than the 22 % reduction in CHD reported for the same magnitude of SBP reduction in clinical trials. Arguably, it is the hypertension treatment paradigm that merits reexamination. Earlier hypertension treatment in all populations prior to the onset of significant pressure-related target organ injury might conceivably prevent, or at least significantly attenuate, the well documented age-related rise in BP seen in most Western societies. In addition, this treatment paradigm might also reduce the significant residual CVD risk observed under the current recommended approach to hypertension treatment. This new approach to therapy would likely have substantial clinical and public health benefits in the high-risk, under-treated African American population that suffers outsized devastating consequences from inadequate control of BP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24370966     DOI: 10.1007/s11906-013-0409-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  31 in total

1.  Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.

Authors:  John M Flack; Domenic A Sica; George Bakris; Angela L Brown; Keith C Ferdinand; Richard H Grimm; W Dallas Hall; Wendell E Jones; David S Kountz; Janice P Lea; Samar Nasser; Shawna D Nesbitt; Elijah Saunders; Margaret Scisney-Matlock; Kenneth A Jamerson
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Low arterial compliance in young African-American males.

Authors:  Adrienne S Zion; Vernon Bond; Richard G Adams; Deborah Williams; Robert E Fullilove; Richard P Sloan; Matthew N Bartels; John A Downey; Ronald E De Meersman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-08       Impact factor: 4.733

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

7.  Racial differences in the outcomes of patients with diastolic heart failure.

Authors:  Mark A East; Eric D Peterson; Linda K Shaw; Wendy A Gattis; Christopher M O'Connor
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

8.  The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.

Authors:  Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak
Journal:  J Hypertens       Date:  2008-07       Impact factor: 4.844

9.  Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010.

Authors:  Fangjian Guo; Di He; Wei Zhang; R Grace Walton
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

10.  Racial disparity in hypertension control: tallying the death toll.

Authors:  Kevin Fiscella; Kathleen Holt
Journal:  Ann Fam Med       Date:  2008 Nov-Dec       Impact factor: 5.166

View more
  6 in total

1.  Associations of Apelin, Visfatin, and Urinary 8-Isoprostane With Severe Hypertension in African Americans: The MH-GRID Study.

Authors:  Steven R Horbal; William Seffens; Adam R Davis; Natalia Silvestrov; Gary H Gibbons; Rakale C Quarells; Aurelian Bidulescu
Journal:  Am J Hypertens       Date:  2016-02-11       Impact factor: 2.689

2.  Recruitment, Retention, and Future Direction for a Heart Health Education and Risk Reduction Intervention Led by Community Health Workers in an African American Majority City.

Authors:  Julie Gleason-Comstock; Cindy Bolden Calhoun; Ghadir Mozeb; Cardell Louis; Alex Hill; Barbara J Locke; Victor Harrell; Sadia Yasmin; Liying Zhang; John M Flack; Nancy T Artinian; Jinping Xu
Journal:  J Racial Ethn Health Disparities       Date:  2022-05-31

3.  The High Blood Pressure-Malaria Protection Hypothesis.

Authors:  Julio Gallego-Delgado; Thomas Walther; Ana Rodriguez
Journal:  Circ Res       Date:  2016-09-22       Impact factor: 17.367

Review 4.  Understanding the Importance of Race/Ethnicity in the Care of the Hypertensive Patient.

Authors:  Keith C Ferdinand; Samar A Nasser
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

5.  Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis.

Authors:  Helen Swede; Amna Sarwar; Anil Magge; Dejana Braithwaite; Linda S Cook; David I Gregorio; Beth A Jones; Jessica R Hoag; Lou Gonsalves; Andrew L Salner; Kristen Zarfos; Biree Andemariam; Richard G Stevens; Alicia G Dugan; Mellisa Pensa; Jessica A Brockmeyer
Journal:  Cancer Causes Control       Date:  2016-03-21       Impact factor: 2.506

Review 6.  Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertension.

Authors:  Kaustav Majumder; Jianping Wu
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.